Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2021

Conditions
Quality of Life
Interventions
COMBINATION_PRODUCT

concurrent chemoradiotherapy (CCRT)

"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1~5 and 29~33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday~Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."

DRUG

Endostar for one cycle

Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5~-1).

DRUG

Endostar for two cycles

Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5~-1 and 24~28).

Trial Locations (1)

600000

Affiliated Hospital of North Sichuan Medical College, Nanchong

All Listed Sponsors
collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

lead

Affiliated Hospital of North Sichuan Medical College

OTHER